Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Reply
  • Published:

Appropriate chemotherapy dosing in obese patients with cancer

Nature Reviews Clinical Oncology volume 10, page 664 (2013)Cite this article

Subjects

Access through your institution
Buy or subscribe

We would like to thank Alessandro Laviano and colleagues for their correspondence on our Review article (Chemotherapy dosing in overweight and obese patients with cancer. Nat. Rev. Clin. Oncol. 10, 451–459; 2013),1 which raised some important issues on the effect of sarcopenia on chemotherapy-related toxicity in obese patients with cancer (Sarcopenia and chemotherapy dosing in obese patients. Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2013.108-c1).2 Although the ASCO clinical practice guidelines on chemotherapy dosing in obese and overweight patients with cancer are based on an exhaustive review of the available clinical literature,3 we acknowledge the complexity of the methods used to measure obesity, as well as the controversy surrounding the definition of obesity.3,4 It should be made clear that, when referring to weight-based dosing, we (and the guideline panel) do not suggest the use of weight alone for calculating chemotherapy dosing in adults. Instead, actual body weight should be used in the calculation of body surface area, which is then used to estimate appropriate chemotherapy dose. The actual measurement of body composition requires sophisticated technology unfamiliar to practicing oncologists and is, therefore, generally not considered in clinical practice.

The prevalence and impact of sarcopenic obesity in patients with cancer clearly needs further investigation. However, a consistent lack of excess toxicity from chemotherapy has been observed in overweight and obese patients who lack other comorbidities and receive full-dose chemotherapy. Thus, the primary recommendation of the guideline panel is to avoid arbitrary dose reductions in these patients based on fear of excess toxicity. The panel recommends that chemotherapy dose and schedule modifications should be similar to those pursued in otherwise healthy weight patients receiving chemotherapy. An additional systematic review of the literature evaluating the toxicity or survival in obese and healthy weight patients receiving cancer chemotherapy has recently been published.5 In this study, which analysed 12 studies and included >9,000 patients with cancer, the investigators found the same or lower rates of toxicity in obese patients with cancer compared with healthy weight individuals with cancer dosed on the basis of actual body weight. Importantly, no difference in overall survival was observed between obese and overweight patients receiving full-dose chemotherapy in this analysis compared with healthy weight individuals with cancer.5 In an additional study of 247 patients receiving induction chemotherapy for acute myeloid leukaemia who were dosed on the basis of actual body weight, no differences were observed in days to neutrophil recovery, duration of hospitalization, infection or other toxicities between obese patients and healthy weight patients.6 We agree with Laviano et al.2 that additional studies of chemotherapy dosing considering fat-free mass and the issue of sarcopenic obesity are warranted and might further improve our ability to tailor appropriate chemotherapy dosing in this population. Nevertheless, the study by Prado et al.7—which reviews the current evidence on sarcopenic obesity and is cited in the correspondence2—highlights the wide heterogeneity and inconsistency of criteria applied to the classification of sarcopenic obesity and its association with disease risk. The relevance of the apparent association between sarcopenia with the pharmacokinetics and dose-limiting toxicities of the tyrosine kinase inhibitor sorafenib in patients receiving myelosuppressive chemotherapy is also unclear.8

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lyman, G. H. & Sparreboom, A. Chemotherapy dosing in overweight and obese patients with cancer. Nat. Rev. Clin. Oncol. 10, 451–459 (2013).

    Article  CAS  Google Scholar 

  2. Laviano, A., Rianda, S. & Rossi Fanelli, F. Sarcopenia and chemotherapy dosing in obese patients. Nat. Rev. Clin. Oncol. http://dx.doi.org/10.1038/nrclinonc.2013.108-c1.

  3. Griggs, J. J. et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 30, 1553–1561 (2012).

    Article  Google Scholar 

  4. American Society of Clinical Oncology. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice guideline data supplement. ASCO [online], (2012).

  5. Hourdequin, K. C., Schpero, W. L., McKenna, D. R., Piazik, B. L. & Larson, R. J. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: a systematic review and meta-analysis. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdt294.

  6. Wenzell, C. M. et al. Outcomes in obese and overweight acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight. Am. J. Hematol. 88, 906–909 (2013).

    Article  CAS  Google Scholar 

  7. Prado, C. M., Wells, J. C., Smith, S. R., Stephan, B. C. & Siervo, M. Sarcopenic obesity: a critical appraisal of the current evidence. Clin. Nutr. 31, 583–601 (2012).

    Article  CAS  Google Scholar 

  8. Mir, O. et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE 7, e37563 (2012).

    Article  CAS  Google Scholar 

  9. Baracos, V. & Kazemi-Bajestani, S. M. Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. Int. J. Biochem. Cell Biol. 45, 2302–2308 (2013).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Comparative Effectiveness and Outcomes Research, Duke University and the Duke Cancer Institute, 2424 Erwin Road, Suite 205, Durham, 27705, NC, USA

    Gary H. Lyman

  2. St Jude Children's Research Hospital, 262 Danny Thomas Place, Mail Stop 313, Memphis, 38105, TN, USA

    Alex Sparreboom

Authors
  1. Gary H. Lyman
    View author publications

    Search author on:PubMed Google Scholar

  2. Alex Sparreboom
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Gary H. Lyman.

Ethics declarations

Competing interests

G. H. Lyman is co-chair and A. Sparreboom is a member of the ASCO Expert Panel involved in formulating the guidelines on appropriate chemotherapy dosing for obese adult patients with cancer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyman, G., Sparreboom, A. Appropriate chemotherapy dosing in obese patients with cancer. Nat Rev Clin Oncol 10, 664 (2013). https://doi.org/10.1038/nrclinonc.2013.108-c2

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.108-c2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing